Cargando…

Immune Senescence Markers Predict the Cellular Immune Response to BNT162b2 Vaccination in Hemodialysis Patients

BACKGROUND: Chronic kidney disease is associated with increased risk of frailty and accelerated immune senescence, potentially affecting the immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. METHODS: Humoral and cellular responses against the spike protein...

Descripción completa

Detalles Bibliográficos
Autores principales:	Van Praet, Jens T, De Groote, Marie, De Bacquer, Dirk, Verhalleman, Ellen, Welvaert, Ziggy, Emmerechts, Jan, Reynders, Marijke, De Vriese, An S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9669454/ https://www.ncbi.nlm.nih.gov/pubmed/36408467 http://dx.doi.org/10.1093/ofid/ofac585

Ejemplares similares

Longevity and Clinical Effectiveness of the Humoral and Cellular Responses to SARS-CoV-2 Vaccination in Hemodialysis Patients
por: De Vriese, An S., et al.
Publicado: (2022)

Longevity and correlation with disease severity of the humoral and cellular response to SARS-CoV-2 infection in haemodialysis patients
por: De Vriese, An S, et al.
Publicado: (2021)

In Reply to ‘Is SARS-CoV-2 Serology Relevant for Hemodialysis Patients With COVID-19?’
por: De Vriese, An S., et al.
Publicado: (2020)

IgG Antibody Response to SARS-CoV-2 Infection and Viral RNA Persistence in Patients on Maintenance Hemodialysis
por: De Vriese, An S., et al.
Publicado: (2020)

Comparison of humoral immune response in heterologous and homologous COVID-19 booster vaccine groups using CoronaVac and mRNA-based BNT162b2 vaccines
por: Atıcı, Serkan, et al.
Publicado: (2023)

Introduction of the BNT162b2 vaccine during a COVID-19 nursing home outbreak
por: McEllistrem, M. Catherine, et al.
Publicado: (2021)

SARS-CoV-2 Humoral and Cellular Immune Responses of Patients With HIV After Vaccination With BNT162b2 mRNA COVID-19 Vaccine in the Tel-Aviv Medical Center
por: Tau, Luba, et al.
Publicado: (2022)

Relative Effectiveness of BNT162b2, mRNA-1273, and Ad26.COV2.S Vaccines and Homologous Boosting in Preventing COVID-19 in Adults in the US
por: Hung Nguyen, Van, et al.
Publicado: (2023)

BNT162b2 Effectiveness Against Delta and Omicron Variants of Severe Acute Respiratory Syndrome Coronavirus 2 in Adolescents Aged 12–17 Years, by Dosing Interval and Duration
por: Ionescu, Iulia G, et al.
Publicado: (2023)

Humoral and Cellular Immune Responses of People Living With Human Immunodeficiency Virus After 3 Doses of Messenger RNA BNT162b2 Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine: A Prospective Cohort Study
por: Tau, Luba, et al.
Publicado: (2023)

Humoral Immune Response of BNT162b2 and CoronaVac Vaccinations in Hemodialysis Patients: A Multicenter Prospective Cohort
por: Clavero, Rene, et al.
Publicado: (2022)

Blunted humoral immune response to the fourth dose of BNT162b2 COVID-19 vaccine in patients undergoing hemodialysis
por: Kanai, Daisuke, et al.
Publicado: (2023)

Adverse Effects and Antibody Titers in Response to the BNT162b2 mRNA COVID-19 Vaccine in a Prospective Study of Healthcare Workers
por: Coggins, Si’Ana A, et al.
Publicado: (2021)

BNT162b2 Vaccine Effectiveness in Preventing Asymptomatic Infection With SARS-CoV-2 Virus: A Nationwide Historical Cohort Study
por: Zacay, Galia, et al.
Publicado: (2021)

Waning Immunity after the BNT162b2 Vaccine in Israel
por: Goldberg, Yair, et al.
Publicado: (2021)

Antibody response to the BNT162b2 vaccine in maintenance hemodialysis patients
por: Attias, Philippe, et al.
Publicado: (2021)

Immune Response Kinetics Following a Third Heterologous BNT162b2 Booster Dose After Primary 2-Dose ChAdOx1 Vaccination in Relation to Omicron Breakthrough Infection: A Prospective Nationwide Cohort Study in South Korea
por: Ahn, Jin Young, et al.
Publicado: (2023)

Correlation of Postvaccination Fever With Specific Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 BNT162b2 Booster and No Significant Influence of Antipyretic Medication
por: Tani, Naoki, et al.
Publicado: (2022)

BNT162b2 Booster Vaccination Induced Immunity against SARS-CoV-2 Variants among Hemodialysis Patients
por: Herman-Edelstein, Michal, et al.
Publicado: (2022)

Decline of immune humoral response after BNT162b2 vaccine
por: Ferri, Sonia, et al.
Publicado: (2022)

Humoral response after BNT162b2 vaccine in Japanese hemodialysis patients
por: Miyazaki, Ryoichi, et al.
Publicado: (2023)

Immunogenicity of a Third Dose of BNT162b2 to Ancestral Severe Acute Respiratory Syndrome Coronavirus 2 and the Omicron Variant in Adults Who Received 2 Doses of Inactivated Vaccine
por: Leung, Nancy H L, et al.
Publicado: (2022)

Immune-Mediated Thrombotic Thrombocytopenic Purpura after BNT162b2 Vaccine
por: Güney, Tekin, et al.
Publicado: (2022)

BNT162b2 COVID-19 Vaccine Induced Immune Thrombocytopenic Purpura
por: Ghosh, A. K., et al.
Publicado: (2022)

Mucosal immune response in BNT162b2 COVID-19 vaccine recipients
por: Azzi, Lorenzo, et al.
Publicado: (2021)

BNT162b2 mRNA Vaccine–Induced Immune Response in Oral Fluids and Serum
por: Seneviratne, Chaminda Jayampath, et al.
Publicado: (2022)

Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis
por: Yau, Kevin, et al.
Publicado: (2021)

Humoral Response to Pfizer BNT162b2 Vaccine Booster in Maintenance Hemodialysis Patients
por: Shashar, Moshe, et al.
Publicado: (2022)

Favorable Humoral Response to Third Dose of BNT162b2 in Patients Undergoing Hemodialysis
por: Kitamura, Mineaki, et al.
Publicado: (2022)

Comparative Immunogenicity and Effectiveness of mRNA-1273, BNT162b2, and Ad26.COV2.S COVID-19 Vaccines
por: Naranbhai, Vivek, et al.
Publicado: (2021)

Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine
por: Li, Chunfeng, et al.
Publicado: (2022)

Systems biological assessment of human immunity to BNT162b2 mRNA vaccination
por: Arunachalam, Prabhu S., et al.
Publicado: (2021)

Severe impairment of T-cell responses to BNT162b2 immunization in patients with multiple myeloma
por: Enßle, Julius C., et al.
Publicado: (2022)

P1584: CELLULAR IMMUNE RESPONSE TO THE BNT162B2 VACCINE IN LYMPHOMA PATIENTS
por: Gurion, R., et al.
Publicado: (2022)

Aspects of Humoral Immunity after Vaccination with Bnt162b2: A Small Study
por: GIUBELAN, LUCIAN-ION, et al.
Publicado: (2022)

Antibody Response in Immunocompromised Patients After the Administration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine BNT162b2 or mRNA-1273: A Randomized Controlled Trial
por: Speich, Benjamin, et al.
Publicado: (2022)

A third dose SARS‑CoV‑2 BNT162b2 mRNA vaccine results in improved immune response in hemodialysis patients
por: Melin, Jan, et al.
Publicado: (2022)

Comparison of four commercial SARS-CoV-2 IgG immuno-assays in RT-PCR negative patients with suspect CT findings
por: Van Praet, Jens T., et al.
Publicado: (2020)

Long-term Antibody Response to the BNT162b2 Vaccine Among Maintenance Hemodialysis Patients
por: Nacasch, Naomi, et al.
Publicado: (2022)

POS-939 EFFICACY OF BNT162b2 VACCINE IN PATIENTS UNDERGOING HEMODIALYSIS IN NORTH OF PORTUGAL
por: FRANCISCO, J., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_k32degk9i80n9u3c6j47vk3383